AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05876767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or repeated dose subcutaneous injection
Trial: NCT06701331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
Trial: NCT05734612
Drug: Placebo (lactose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
Trial: NCT06058039
Drug: NMRA-335140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Trial: NCT06058039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally
Trial: NCT06093230
Drug: Deuremidevir Hydrobromide Tablets
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JT001 single dose, 0.3g
Trial: NCT05065710
Drug: ZL-1211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
Trial: NCT06273501
Drug: Magtrace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive superficial and interstitial injection with a 23 G needle with of a total volume of 0.1 - 1 ml Magtrace at four sites in or near the tumor in vulva, the same localization as the injections of Technetium99m and Patent blue for tracing SLNs performed at the surgery. The injection is performed by one of the gynecologic cancer surgeons participating in this study.The time of migration of SPIO to the groin nodes is not known for vulvar cancer. Transportation by dynamic MRI, with selective sequences repeated during a time span of 1- 60 minutes after the injection.
Trial: NCT05869812
Drug: CaHMB (Dietary supplement, not Drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
Trial: NCT05990985
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.
Trial: NCT03763305
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
Trial: NCT03763305
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl intravenous injection for anesthetic induction
Trial: NCT04823208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05881525
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Trial: NCT06291116
Drug: standard care for 24 months.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard care for 24 months.
Trial: NCT06121700
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks.
Trial: NCT04855565
Drug: ALY688-SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose subcutaneous injection
Trial: NCT06172634
Drug: dentritic cell infusion and immunecheckpoint inhibitor
RxNorm normalized name: foslevodopa and decarboxylase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dentritic cell infusion and immunecheckpoint inhibitor
Trial: NCT04969497
Drug: Treatment A: M207 3.8 mg MiniMac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups
Trial: NCT04969497
Drug: Treatment B: M207 3.8 mg MACAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups
Trial: NCT05035277
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
Trial: NCT05786846
Drug: Iodinated contrast agents
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who use iodinated contrast agents clinically
Trial: NCT06633601
Drug: Definity Suspension for Injection
RxNorm normalized name: Definity Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbubble contrast agents for ultrasound
Trial: NCT06301906
Drug: LipoCol Forte Capsule 600mg bid
RxNorm normalized name: aspirin 600 MG [Palaprin Forte]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipoCol Forte Capsule 600mg bid for 12 months
Trial: NCT06339697
Drug: different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate)
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation with different types of laxatives (compounded polyethylene glycol electrolytes and compounded sodium picosulfate)
Trial: NCT03446807
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
Trial: NCT04775615
Drug: DDO-3055 tablets；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose：DDO-3055 tablets for 7 days or Placebo for 7 days
Trial: NCT04775615
Drug: DDO-3055 tablets；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose：DDO-3055 tablets for 7 days or Placebo for 7 days
Trial: NCT04775615
Drug: DDO-3055 tablets；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose：DDO-3055 tablets for 7 days or Placebo for 7 days
Trial: NCT05443178
Drug: Nivaquine ® (Chloroquine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalation and extension trial
Trial: NCT05649618
Drug: Cyclophosphamide Capsules
RxNorm normalized name: Cyclophosphamide Capsules
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Trial: NCT05047159
Drug: drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no restriction on the choice of therapeutic drugs.
Trial: NCT05474690
Drug: (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of ECHP-THP regimen: epirubicin 90mg/m2+cyclophosphamide 600mg/m2 followed by docetaxel 90mg/m2, trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg /kg) + Pertuzumab (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
Trial: NCT05081986
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to cycloserine capsule
Trial: NCT05721287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% sodium chloride \[NaCl\]) administered as a single dose IV infusion over 60 minutes
Trial: NCT05985629
Drug: IPACK
RxNorm normalized name: Emend TriPack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration between the popliteal artery and capsules of the knee (IPACK) is a novel ultrasound-guided technique that provides additional regional analgesic relief to the posterior aspect of the knee without complications seen in a sciatic nerve block. The intention of the IPACK block is to anesthetize the terminal sensory nerves while sparing the main trucks of the common peroneal and tibial nerves.
Trial: NCT05985629
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive the normal pre-procedure care including a pre-operative visit, surgery, and post-operative care. The control group will receive a sham block consisting of saline in the same anatomical location and manner that the intervention IPACK block is administered.
Trial: NCT06716151
Drug: HB0034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody
Trial: NCT06716151
Drug: HB0034 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB0034 matching Palcebo
Trial: NCT03523338
Drug: ADT (Standard of Care)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
Trial: NCT06733935
Drug: NKX019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK
Trial: NCT06733935
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepletion
Trial: NCT06732648
Drug: HRS8179 blank preparation.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS8179 blank preparation.
Trial: NCT04261387
Drug: LUT014 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application qd for 28 days
Trial: NCT04261387
Drug: Placebo for LUT014 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for qd topical application for 28 days
Trial: NCT06733519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to TH-104
Trial: NCT06381557
Drug: Zhengyuan Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhengyuan capsules, 4 capsules at a time, 3 times per day;
Trial: NCT06381557
Drug: Placebo contains 5%-10% Zhengyuan Capsule total mixed powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhengyuan capsules simulator（Placebo contains 5%-10% Zhengyuan Capsule total mixed powder）, 4 capsules at a time, 3 times per day;
Trial: NCT06251089
Drug: CPC mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07% CPC mouthwash
Trial: NCT06251089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo of the CPC mouthwash
Trial: NCT06372184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days
Trial: NCT04284059
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
Trial: NCT05477108
Drug: Treatment A (BGF MDI HFO with oral activated charcoal)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
Trial: NCT05477108
Drug: Treatment B (BGF MDI HFA with oral activated charcoal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
Trial: NCT05137119
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin
Trial: NCT04950881
Drug: Bradycardia Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
Trial: NCT05759234
Drug: HS248 pieces
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
Trial: NCT04736745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for solution for injection
Trial: NCT04168879
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
Trial: NCT04187547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
Trial: NCT04412395
Drug: Placebo of excipient(s) will be administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of the equivalent excipient will be administered to placebo group
Trial: NCT05507411
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200mg Q3W
Trial: NCT03890341
Drug: Drospirenone/Ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
Trial: NCT00348582
Drug: Ketorolac, Nepafenac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002344
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05524194
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
Trial: NCT04833023
Drug: Haldol 2mg/ml oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN).
Trial: NCT05808725
Drug: Norvasc 5 mg tablets of Pfizer Labs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norvasc 5 mg is given to R Fasting
Trial: NCT04978493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04667117
Drug: iDMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
Trial: NCT04815551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is sterile liquid for IV infusion.
Trial: NCT05304910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
Trial: NCT05850689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules administered orally, once daily
Trial: NCT01511835
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid 400mcg; 1 cp/die
Trial: NCT05220228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose / sucrose placebo
Trial: NCT05016869
Drug: fruquintinib plus capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W
Trial: NCT05553678
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
Trial: NCT02503176
Drug: KCT-0809 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05618353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05020652
Drug: TQ05105 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.
Trial: NCT04724655
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
Trial: NCT04686448
Drug: propofol-fentanyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
Trial: NCT05761431
Drug: SYHX2008 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration on Day 1.
Trial: NCT05761431
Drug: Sandostatin ® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration on Day 1.
Trial: NCT05761431
Drug: Placebo to SYHX2008 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration on Day 1.
Trial: NCT06042647
Drug: 0.01% Halobetasol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
Trial: NCT05553691
Drug: SPL026
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT04182490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical appearing placebo
Trial: NCT04393883
Drug: A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
Trial: NCT04393883
Drug: B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Trial: NCT04597320
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer.
Trial: NCT06196762
Drug: XKH002 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg/4 mL/vial（60 mg/mL）
Trial: NCT05054023
Drug: Soulagel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topic gel
Trial: NCT05054023
Drug: Arthrosyl®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topic gel
Trial: NCT04773587
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream - Vehicle
Trial: NCT05814523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as IV solution.
Trial: NCT05814523
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
Trial: NCT04782323
Drug: aQII-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Trial: NCT04782323
Drug: aQII-3 Investigational
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.